Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including mRNA, siRNA, replicon RNA, asRNA, DNA, and gene editing therapeutics.
The latest price target for Arcturus Therapeutics (NASDAQ:ARCT) was reported by Canaccord Genuity on March 10, 2025. The analyst firm set a price target for $68.00 expecting ARCT to rise to within ...
Explore Arcturus Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ARCT. Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback